Utilizing Nano-Sized Erbium Borate Particles to Achieve Scarless Wound Closure, a Wound Healing Product Containing Erbium Borate Nanoparticles, and the Production Method of Erbium Borate Particles.

TR202017756BActive Publication Date: 2026-10-21YEDITEPE UNIVERSITESI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TR202017756
Authority / Receiving Office
TR · TR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-11-06
Publication Date
2026-10-21
Estimated Expiration
2040-11-06

AI Technical Summary

Technical Problem

Existing wound healing technologies are ineffective in healing wounds quickly, often result in chronicity due to inflammation, and leave scars, while being costly.

Method used

The use of nano-sized erbium borate particles in wound healing compositions to enhance wound closure by promoting rapid absorption and preventing scarring, synthesized through a precipitation method using sodium hydroxide and boric acid.

Benefits of technology

Erbium borate nanoparticles facilitate rapid, scarless wound healing by enhancing cell viability, reducing inflammation, and regulating gene expression for tissue regeneration, offering a cost-effective alternative.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000012_0000
    Figure 00000012_0000
  • Figure 00000012_0001
    Figure 00000012_0001
  • Figure 00000013_0000
    Figure 00000013_0000
Patent Text Reader

Abstract

This invention relates to the use of nano-sized erbium borate, which has been found to exhibit a significant healing effect on cells in terms of its scarless wound healing effect. The aim of the invention is to heal wounds quickly and effectively, to prevent inflammation during the wound healing process, and to prevent scarring in the skin areas of closed wounds.
Need to check novelty before this filing date? Find Prior Art

Description

Utilizing Nanoscale Erbium Borate Particles to Achieve Scarless Wound Closure, a Wound Healing Product Containing Erbium Borate Nanoparticles, and the Production Method of Erbium Borate Particles. Technical Area This invention relates to the use of nano-sized erbium borate, which has been found to have a significant healing effect on cells in terms of its scarless wound healing effect. Previous Technique The biology of wound healing is a complex, multifaceted system that has been studied for many years. Today, research is rapidly progressing to develop new treatment methods for wounds that are fast, leave no scars, and minimize visual discomfort for the patient. The increasing prevalence of conditions like diabetes and high blood pressure, which cause difficult-to-treat chronic wounds, makes the development of new wound treatment methods a necessity. The development of modern treatment methods that take advantage of new discoveries, especially in the treatment of chronic wounds, is of great importance. Chronic wounds are wounds that do not heal sufficiently within a month in the normal treatment process and cause a serious decrease in the quality of life of their patients. These types of wounds, which can last from 12 to 16 months and have a recurrence rate of 60 to 70 percent [1], affect the mental health of their patients as well as their physical health. These long-term illnesses have also become a serious financial burden on health systems worldwide. In 2015, the UK spent 5.3 billion pounds [2], and in 2012, in America, diabetic ulcer treatments alone cost between 9 and 13 billion dollars [3]. Especially in developed countries, the aging population and advancing This will bring about an increase in such problems and the financial difficulties they bring with them in the years 25418.107. The wound healing process can be considered in four separate steps. The first step is hemostasis, or stopping the bleeding. As soon as a wound occurs, the blood vessels in the wound area constrict, slowing blood flow. Then, platelet cells come together to close the gaps in the vessels. Finally, coagulation occurs, where platelet cells are brought together with fibrin filaments. Hemostasis begins the moment a wound opens and happens very quickly. Following hemostasis, inflammation begins, with immune system cells being brought to the wound area. These cells remove damaged cells, bacteria, and other pathogens from the area. Inflammation results in redness, pain, and a feeling of warmth in the wound area. After these first two processes, the permanent repair of the wound begins.During the proliferation process, the tissue in the wound area is regenerated with proteins secreted by new cells, and vascularization occurs to provide nutrients to the new tissue. Finally, in the maturation or redesign step of the wound, programmed death of cells that come to the area to repair the wound but are no longer needed for their functions takes place, and the proteins that form the new tissue are rearranged, softening the tissue and making it more resistant [4]. Traditional wound treatment involves covering the wound with a dressing made of various materials and containing different agents. One of the biggest advancements in this field was the realization in the 1960s that keeping the wound surface moist plays a crucial role in the wound healing process. For effective wound treatment, the wound bed must be kept moist and allow for oxygen flow, while the wound is protected from physical factors and microorganisms. Although many different methods and agents are used today to provide protection against microorganisms and accelerate wound healing, none of these methods show the same success in every wound. Acute-chronic, different Wounds, arising from various causes and located in different parts of the body, require different treatment methods to ensure optimal healing conditions for each type of wound. Different nanoparticles have been shown to be effective in wound treatment. Nanoparticles with known antimicrobial effects, such as silver nanoparticles, both accelerate wound healing and reduce the risk of infection by protecting the wound from microorganisms (US 2005 / 0022721). Literature indicates that the active ingredients in drugs used to increase cell division rate and promote wound repair and healing do not possess significant anti-inflammatory or cell division rate-increasing properties. Studies in the literature show that while they may increase cell division rates in the wound area, they fail to inhibit the formation of new scar tissue, thus hindering the scar tissue remodeling process. In the European patent application document numbered EP775492, known applications in the field are described for the use of lanthanide, tin, zinc, manganese, yttrium, cobalt, and strontium salts for (i) the treatment of pain associated with at least one cutaneous disorder, (ii) the control of hypertrophic wound healing (scarring), and / or (iii) the treatment of acne rosacea. Among the lanthanide salts used in the invention are dysprosium and erbium salts, and borate is also among the ions in these salts. Nanoparticle form and salts of an element exhibit different properties. Even two different nanoparticles of the same element can show different characteristics and be applied in different ways depending on the production method. The European patent application document numbered EP770392 describes known applications in the field of cosmetics, dermatological or pharmaceutical compositions involving manganese, yttrium or specific lanthanide salts, particularly in the treatment of sensitive skin. The lanthanide salts used in the invention include dysprosium and erbium salts, and borate is among the ions in these salts. 25418.107 In the Chinese patent application document numbered CN1329068C, regarding known applications in the field, it is argued that plant-based oils and extracts in cosmetic, dermatological, or pharmaceutical compositions induce wound regeneration and promote wound healing without leaving scars. Some of the technical problems encountered in applications within the known state of the art can be listed as follows: > Ineffective wound healing. > The wound healing process is lengthy. > The likelihood of the condition becoming chronic increases due to inflammation occurring as the wounds heal. > Scarring remains in healed wounds. > The high cost of wound-healing formulations on the market. Brief Description of the Invention The aim of the invention is to ensure rapid and effective wound healing, to prevent inflammation during the wound healing process, and to prevent scarring in the skin areas of closed wounds. Another objective of the invention is to use the material in nanoparticle sizes to ensure high absorption by the skin and rapid onset of effect. Another objective of the invention is to be more cost-effective than the known state of the art. Detailed Description of the Invention The purpose of this invention was achieved through the study titled "Utilization of Nano-Sized Erbium Borate Particles to Ensure Scarless Wound Closure, A Wound Healing Agent Containing Erbium Borate Nanoparticles". 25418.107 The "Production Method of the Product and Erbium Borate Particles" is shown in the attached figures; from these figures: Figure 1 - Illustration of the graph characterizing the concentration and size of Erbium Borate nanoparticles used in the invention by nanoparticle tracking analysis (NTA). Figure 2 - Graphical representation of the cell viability percentage of control groups treated and untreated with different concentrations of Erbium Borate nanoparticles on days 1 and 2 within the scope of the invention. Figure 3 - Microscopic image of cells with a cut in the middle, treated with Erbium Borate nanoparticles at 0 and 20 hours, and of untreated control groups, within the scope of the invention. Figure 4 - Graphical representation of the length of the scratch width in cells with a central scratch, treated with and without Erbium Borate nanoparticles at 0 and 20 hours, within the scope of the invention. Figure 5 - Graphical representation of the area of ​​the scratch width in cells with a central scratch within the scope of the invention, treated with and without Erbium Borate nanoparticles at 0 and 20 hours. Figure 6 - Graphical representation of Reactive Oxygen formation in cells with a cut in the middle, treated with Erbium Borate nanoparticles, in a negative control group that was not treated, and in a positive control group where ROS was generated. Figure 7 - Graphical representation of the measurement of levels of intercellular matrix genes, which are important in scarless wound closure, in cells with a cut in the middle, treated with Erbium Borate nanoparticles and in untreated negative control groups. Figure 8 - Negative control of cells with a cut in the middle, treated and untreated with Erbium Borate nanoparticles, within the scope of the invention. This is a graphical representation of the measurement of TGFB gene levels, which are important in scarless wound closure, in groups 25418.107. Figure 9 - Graphical representation of the measurement of levels of MMP genes, which organize the intercellular matrix important in scarless wound closure, in cells with a cut in the middle, treated with Erbium Borate nanoparticles, and in untreated negative control groups. Figure 10 - Graphical representation of the measurement of inflammation genes, which are important in scarless wound closure, in cells with a cut in the middle, treated with Erbium Borate nanoparticles and in untreated negative control groups. Figure 11 - Graphical representation of the measurement of Fibromodulin gene levels, which plays a key role in scarless wound closure and ensures that the wound closes without scarring, in cells with a cut in the middle, treated with Erbium Borate nanoparticles, and in untreated negative control groups. The invention relates to nano-sized erbium borate (ErBOs Er(BOa)3) particles, which have been found to exhibit a significant therapeutic effect on cells and are used in scarless wound healing treatment. Within the scope of this invention, the technical advantages obtained when using erbium borate nanoparticles in different compositions were observed through experimental studies. In in vivo studies, wound closure was investigated by applying a solution containing different carriers with compositions ranging from 2 to 20 pg / ml in a single application. Experimental Studies Preparation of erbium borate nanoparticles The invention involves the synthesis of nano-sized (below 100 nm) erbium borate compounds developed for use in the wound healing process, in buffered form. 25418.107 is synthesized using the precipitation method at room temperature. The steps of this synthesis method are as follows: 1- Sodium hydroxide and boric acid are mixed together in a 1:2 stoichiometric ratio and dissolved in pure water to prepare a borate buffer (NaOH / HsBCh buffer solution) with a pH between 9 and 9.5, capable of maintaining the pH of the reaction medium within this range. 2- In a separate beaker, erbium nitrate (and preferably PEG (between 400 and 20000 Da)) is dissolved in 200 ml of pure water at a stoichiometric ratio of 1:1.5. The erbium nitrate (and preferably PEG) solution and the borate buffer solution are mixed with a mechanical stirrer at 2000 rpm for 30 minutes. 3- The resulting product is washed four times in pure water to remove impurities, and then dried at 60°C for 24 hours. 1. Cell culture Keratinocyte cells (HACAT) derived from human skin were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (Invitrogen) and 1% PSA (Biological Industries, Beit Haemek, Israel) at 37°C and 5% CO2 in cell culture incubators. 2. Toxicity Cells were seeded into 96-well culture dishes (Corning Glasswork, Corning, NY) at a concentration of 5,000 cells per well in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (Invitrogen) and 1% PSA (Biological Industries, Beit Haemek, Israel). Cell viability was measured on days 1 and 2. Cell viability was determined using the 3-(4,5-dimethyl-thiazol-2-yl)-5-(3-carboxy-methoxy-phenyl)-2-(4-sulfo-phenyl)-2Htetrazolium (MTS) method (CellTiter96 AqueousOne Solution; Promega, Southampton, UK). 100μl of MTS solution was added to cells in 100μl of medium and incubated for 2 hours in the dark at 37°C. ELISA at 490 nm wavelength after incubation period. Viability analysis was observed by measuring absorbance using a plate reader device (Biotek, Winooski, VT) with registration number 25418.107. 3. Wound Healing The wound scratch method was used to determine the migration potential of keratinocyte cells (HACAT) originating from human skin. In this method, cells were seeded into 24-well plates in triplicate, with 10,000 cells per well. After 24 hours, the single layer of cells was incised in a straight direction using a 200 pl pipette tip, and the closure of the resulting wound bed was observed. After incision, the culture medium above the cells was removed, and non-toxic doses of Erbium Borate were added to all groups except the control group, according to the results obtained from toxicology tests. Wound bed closure was measured at 0 and 20 hours using the Carl Zeiss AxioVision Rei. 4.8 software program, and the wound closure process was evaluated by comparing the Erbium Borate application groups and the control group. 4. Real-Time Polymerase Chain Reaction Real-time polymerase chain reaction (RPC) assays are performed to observe changes in gene levels in cells treated with erbium borate. These changes occur at both morphological and gene expression levels. The primers used were designed using Primer BLAST software (The National Center for Biotechnology = NCBI). Total RNAs were isolated from the cells, and cDNA synthesis was performed. The synthesized cDNAs were mixed with primers in Fermentas Maxima SYBR Green mixture to a final volume of 20 μΐ, and the gene expression levels were analyzed using a BIO-RAD instrument. 5. Characterization of Erbium Borate Nanoparticles Size distributions of erbium nanoparticles were determined using a Nanosight NS300 (Malvem Instruments) device with a 488 nm laser. Samples were diluted to the concentrations recommended by the device, and a camera image was taken from each sample. Three 30-second images were acquired at level 10 of 25418.107. The sample cuvette was cleaned with fresh samples between each image acquisition. Samples were analyzed using NTA software version 3.3 at the threshold values ​​recommended by the instrument. 6. Measuring Reactive Oxygen Levels Analysis of intracellular ROS derivatives produced during wound healing by erbium nanoparticles was performed using DCF-DA (Abeam). Following attachment, HaCaT cells were treated with erbium borate for 16 hours. The cells were then washed with PBS and stained with DCF-DA (5 μM) and Hoechst stain for 30 minutes at 37 degrees Celsius in the dark. After re-washing, the cells were incubated for 2 hours at 37 degrees Celsius in serum-free and phenol red-free DMEM medium containing 200 μM hydrogen peroxide. Following incubation, Horasan radiation was measured using a Varioskan LUX Horasan microplate reader. DCF-DA radiation was normalized by dividing it by Hoechst radiation. The advantages gained within the scope of the invention can be expressed as follows: • Effective wound healing, • Prevention of inflammation during wound healing, • Absence of scarring in closed wound areas, • Rapid regeneration of wounds to their natural tissue form, • High absorption of nanoparticles by the skin due to their size and rapid onset of action, • The formulation developed within the scope of this invention, containing erbium borate nanoparticles as the active ingredient, being more cost-effective compared to other techniques, • Erbium borate nanoparticles used as the active ingredient being more effective than other active ingredients used for similar purposes in the current state of the art. 25418.107 Sources 1. Tian, ​​Jun, et al. Topical delivery of silver nanoparticles promotes wound healing. ChemMedChem 2.1 (2007): 129-136. 2. Guest, J. F., Ayoub, N., Mcllwraith, T., Uchegbu, I., Gerrish, A., Weidlich, D.,... & Vowdcn, P. (2015). Health economic burden that wounds impose on the National Health Service in the UK. BMJopen, 5(12), e009283. 3. Rice, J. Bradford, et al. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes care 37.3 (2014): 651-658. 4. Armstrong, David G., Andrew JM Boulton, and Sicco A. Bus. Diabetic foot ulcers and their recurrence. New England Journal of Medicine 376.24 (2017): 2367-2375. 5. Martin, Paul, and R. Nunan. Cellular and molecular mechanisms of repair in acute and chronic wound healing. British Journal of Dermatology’ 173.2 (2015): 370-378.

Claims

1. The invention describes nano-sized erbium borate (ErBOs - Er(BO2)3) particles that have been found to have a significant therapeutic effect on cells and are used for scarless wound healing treatment.

2. A wound healing product, as described in Claim 1, consisting of nano-sized erbium borate (ErBOs - Er(BO2)s) particles in compositions of 2 to 20 µg / ml and their carriers, which has been found to have a significant therapeutic effect on cells and to provide scarless wound healing treatment.

3. This is a production method based on buffered precipitation at room temperature for nano-sized erbium borate particles incorporated into a wound healing product, as described in Claim 2, and involves the following steps: - Mixing sodium hydroxide and boric acid in a 1:2 stoichiometric ratio; - Preparing a borate buffer (NaOH / HaBCh buffer solution) with a pH between 9 and 9.5, capable of maintaining the pH of the reaction medium within this range, by dissolving the mixture in pure water; - Dissolving erbium nitrate in 200 ml of pure water in a separate beaker in a 1:1.5 stoichiometric ratio; - Mixing the erbium nitrate solution and the borate buffer solution under a mechanical stirrer at 2000 rpm for 30 minutes; - Washing the resulting product four times in pure water to remove impurities, followed by drying at 60 °C for 24 hours; - Obtaining erbium nanoparticles. He is drinking.

4. In the production method of nano-sized erbium borate particles, which are included in a wound healing product as in Claim 3, PEG is added to the erbium nitrate solution in the range of 400 to 20000 Da.